Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity

Ting Sun1, Wanlin Zhan2, Lijiang Wei2

  • 1Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. beibeisun2008@163.com.

Insights

Higher levels of angiopoietin-like 3 (ANGPTL3) and lower levels of angiopoietin-like 4 (ANGPTL4) are associated with coronary atherosclerosis. These proteins may serve as future predictors for the condition.

Area of Science:

  • Cardiovascular Research
  • Biomarker Discovery
  • Atherosclerosis Pathogenesis

Background:

  • Investigated the role of ANGPTL3 and ANGPTL4 in atherosclerosis.
  • Examined the relationship between plasma ANGPTL3/ANGPTL4 levels and coronary stenosis severity.

Purpose of the Study:

  • To determine the association between ANGPTL3 and ANGPTL4 levels and the degree of coronary artery stenosis.
  • To evaluate ANGPTL3 and ANGPTL4 as potential predictors of coronary atherosclerosis.

Main Methods:

  • 305 patients with angina undergoing coronary angiography were enrolled.
  • ANGPTL3 and ANGPTL4 levels were quantified using competitive ELISA kits.
  • Patients were categorized based on coronary artery stenosis severity.

Main Results:

  • Higher plasma ANGPTL3 and lower ANGPTL4 levels were observed in patients with coronary artery stenosis ≥10% compared to those with <10%.
  • ANGPTL3 and ANGPTL4 levels significantly correlated with the severity of coronary vascular stenosis.
  • ROC analysis identified specific thresholds for ANGPTL3 and ANGPTL4 as predictors of atherosclerosis, with significant odds ratios indicating independent risk factor status.

Conclusions:

  • Elevated ANGPTL3 and reduced ANGPTL4 levels are linked to coronary atherosclerosis.
  • ANGPTL3 and ANGPTL4 show potential as future biomarkers for predicting coronary atherosclerosis.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
86
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
479
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
81
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
391
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
174